ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $454,237 | +78.3% | 16,905 | +68.6% | 0.00% | +200.0% |
| Q2 2023 | $254,736 | 0.0% | 10,029 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $254,736 | -59.9% | 10,029 | -36.0% | 0.00% | -75.0% |
| Q4 2022 | $635,291 | +24.6% | 15,663 | +1.3% | 0.00% | +33.3% |
| Q3 2022 | $510,000 | +44.9% | 15,462 | +54.5% | 0.00% | +50.0% |
| Q2 2022 | $352,000 | -23.3% | 10,007 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $459,000 | -30.9% | 10,007 | -0.1% | 0.00% | -33.3% |
| Q4 2021 | $664,000 | +6.4% | 10,018 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $624,000 | -24.9% | 10,007 | -0.3% | 0.00% | -25.0% |
| Q2 2021 | $831,000 | +25.3% | 10,038 | +0.3% | 0.00% | 0.0% |
| Q1 2021 | $663,000 | -13.7% | 10,007 | -0.1% | 0.00% | 0.0% |
| Q4 2020 | $768,000 | +78.6% | 10,018 | +0.2% | 0.00% | +33.3% |
| Q3 2020 | $430,000 | -0.5% | 10,000 | -0.3% | 0.00% | 0.0% |
| Q2 2020 | $432,000 | -36.3% | 10,028 | -6.3% | 0.00% | 0.0% |
| Q1 2020 | $678,000 | 0.0% | 10,697 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $678,000 | +126.8% | 10,697 | +0.5% | 0.00% | +200.0% |
| Q3 2019 | $299,000 | +9.9% | 10,643 | +3.7% | 0.00% | 0.0% |
| Q2 2019 | $272,000 | +48.6% | 10,267 | +2.7% | 0.00% | 0.0% |
| Q1 2019 | $183,000 | +47.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $124,000 | -35.1% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $191,000 | +40.4% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $136,000 | +277.8% | 10,000 | 0.0% | 0.00% | – |
| Q1 2018 | $36,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q4 2017 | $36,000 | +71.4% | 10,000 | +100.0% | 0.00% | – |
| Q3 2017 | $21,000 | +133.3% | 5,000 | 0.0% | 0.00% | – |
| Q2 2017 | $9,000 | 0.0% | 5,000 | 0.0% | 0.00% | – |
| Q1 2017 | $9,000 | +28.6% | 5,000 | 0.0% | 0.00% | – |
| Q4 2016 | $7,000 | -90.4% | 5,000 | -50.0% | 0.00% | – |
| Q3 2016 | $73,000 | +37.7% | 10,000 | 0.0% | 0.00% | – |
| Q2 2016 | $53,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |